Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma

Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pongas, Georgios, Cheson, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331102/
https://www.ncbi.nlm.nih.gov/pubmed/34354386
http://dx.doi.org/10.2147/BLCTT.S267569
_version_ 1783732849516478464
author Pongas, Georgios
Cheson, Bruce
author_facet Pongas, Georgios
Cheson, Bruce
author_sort Pongas, Georgios
collection PubMed
description Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor–T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.
format Online
Article
Text
id pubmed-8331102
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83311022021-08-04 Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma Pongas, Georgios Cheson, Bruce Blood Lymphat Cancer Review Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor–T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL. Dove 2021-07-30 /pmc/articles/PMC8331102/ /pubmed/34354386 http://dx.doi.org/10.2147/BLCTT.S267569 Text en © 2021 Pongas and Cheson. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Pongas, Georgios
Cheson, Bruce
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
title Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
title_full Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
title_fullStr Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
title_full_unstemmed Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
title_short Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
title_sort recent advances in the management of patients with relapsed/refractory follicular lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331102/
https://www.ncbi.nlm.nih.gov/pubmed/34354386
http://dx.doi.org/10.2147/BLCTT.S267569
work_keys_str_mv AT pongasgeorgios recentadvancesinthemanagementofpatientswithrelapsedrefractoryfollicularlymphoma
AT chesonbruce recentadvancesinthemanagementofpatientswithrelapsedrefractoryfollicularlymphoma

Ejemplares similares